Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck

被引：0
|
作者：
Jacques Bernier
机构：
[1] Genolier,J Bernier is Chairman of the Radio
[2] Switzerland.,Oncology Division at the Genolier Swiss Medical Network
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck have a poor prognosis. Cetuximab represents a clinically relevant advance in the treatment of recurrent and metastatic disease. This rationale for cetuximab as monotherapy and its use in combination with platinum-based chemotherapy for recurrent and/or metastatic disease in the first-line setting is discussed.
引用
收藏
页码：705 / 713
页数：8
相关论文
共 50 条
  • [31] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    del Campo, J. M.
    Clement, P. M.
    Hitt, R.
    Degardin, M.
    Zhang, W.
    Blackman, A.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1813 - 1820
  • [32] Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
    Uozumi, Shinya
    Enokida, Tomohiro
    Suzuki, Shinya
    Nishizawa, Aya
    Kamata, Hayato
    Okano, Tomoka
    Fujisawa, Takao
    Ueda, Yuri
    Okano, Susumu
    Tahara, Makoto
    Yamaguchi, Masakazu
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [33] Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
    Vermorken, J. B.
    Licitra, L.
    Stoehlmacher-Williams, J.
    Dietz, A.
    Lopez-Picazo, J. M.
    Hamid, O.
    Hossain, A. M.
    Chang, S. -C.
    Gauler, T. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2877 - 2883
  • [34] Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report
    Gibson, M. K.
    Kies, M.
    Kim, S.
    Savvides, P.
    Kotsakis, A.
    Blumenschein, G.
    Worden, F.
    Chen, H.
    Grandis, J.
    Argiris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck
    Shin, Dong M.
    Khuri, Fadlo R.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2013, 35 (03): : 443 - 453
  • [36] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Lasniska, Izabela
    Kolenda, Tomasz
    Teresiak, Anna
    Lamperska, Katarzyna M.
    Galus, Lukasz
    Mackiewicz, Jacek
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
  • [37] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, Hsiang-Fong
    Huang, Huai-Cheng
    Liao, Bin-Chi
    Hong, Ruey-Long
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [38] Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck
    Mirabile, Aurora
    Miceli, Rosalba
    Calderone, Rosa Gioia
    Locati, Laura
    Bossi, Paolo
    Bergamini, Cristiana
    Granata, Roberta
    Perrone, Federica
    Mariani, Luigi
    Licitra, Lisa
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (06): : 1895 - 1902
  • [39] Prognostic Factors in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haring, C. T.
    Rosko, A.
    Heft-Neal, M. E.
    Shuman, A.
    Brenner, J. C.
    Worden, F.
    Spector, M. E.
    Swiecicki, P. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1177 - 1177
  • [40] Vinorelbine and carboplatin in recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Kornek, V
    Scheithauer, W
    Glaser, C
    Toth, J
    Duman, M
    Formanek, M
    Hejna, M
    Kornfehl, J
    ONCOLOGY, 1999, 56 (01) : 24 - 27
12345